Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSURB447 is a cannabinoid 1 (CB1) receptor antagonist and CB2 receptor agonist.1 It inhibits the binding of the CB receptor agonist [3H]-WIN 55,212-2 to CHO-K1 cells expressing the human CB2 receptor or rat cerebellar membranes (IC50s = 41 and 313 nM, respectively). URB447 (20 mg/kg) reduces food intake and weight gain in ob/ob mice and reverses (R)-methanandamide-induced analgesia in mice. It decreases infarct volume and demyelination in a neonate rat model of hypoxia-ischemia-induced brain injury when administered at a dose of 1 mg/kg.2
WARNING This product is not for human or veterinary use.
1. Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-
2. The synthetic cannabinoid URB447 reduces brain injury and the associated white matter demyelination after hypoxia-